Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| China-Japan Friendship Hospital | OTHER |
| Beijing Municipal Health Commission | OTHER_GOV |
Not provided
Not provided
Not provided
Not provided
This is a multicenter, randomized controlled trial designed to evaluate the impact of tNGS in patients with community-acquired pneumonia who experience initial treatment failure.
Community-acquired pneumonia (CAP) is a common respiratory disease and poses a major threat to global health. CAP can be caused by a wide range of respiratory pathogens, including viruses, bacteria, and fungi. However, conventional microbiological tests often fail to identify the causative pathogens, making etiological diagnosis challenging and limiting the implementation of individualized treatment strategies, which may affect patient prognosis.
Targeted next-generation sequencing (tNGS) enables the simultaneous detection of hundreds of common respiratory pathogens at a relatively low cost and has significantly improved pathogen detection rates. To further evaluate the impact of tNGS on clinical decision-making and patient outcomes in real-world practice, a multicenter randomized controlled trial is proposed by the investigators, enrolling patients with community-acquired pneumonia who experience initial treatment failure. Participants will be randomly assigned in a 1:1 ratio to either the tNGS group or the conventional testing group. Patients in the tNGS group will undergo tNGS in addition to conventional microbiological testing, whereas those in the conventional testing group will receive conventional microbiological testing alone. Length of hospital stay and other clinical effectiveness endpoints will be compared between the two groups.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| tNGS group | Experimental | Lower respiratory tract samples collected (BALF, sputum); undergo targeted next-generation sequencing in addition to conventional microbiological testing; follow-up by telephone on day 30 (D30). |
|
| Control group | Active Comparator | Lower respiratory tract samples collected (BALF, sputum); undergo conventional microbiological testing; follow-up by telephone on day 30 (D30). |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Targeted next-generation sequencing | Diagnostic Test | Bronchoalveolar lavage fluid (BALF) or sputum samples will be collected within 72 hours after randomization and sent for targeted next-generation sequencing (tNGS). The test results will be reported to the attending physician within 1-2 days. |
| Measure | Description | Time Frame |
|---|---|---|
| Length of hospital stay | Defined as the total number of hospital days by Day 30. | 30 days |
| Measure | Description | Time Frame |
|---|---|---|
| 30-day mortality | Defined as the proportion of patients who died by Day 30. | 30 days |
| ICU admission rate | Defined as the incidence of transfer to the ICU within 30 days of randomization for patients initially admitted to a general ward. |
| Measure | Description | Time Frame |
|---|---|---|
| Pathogen detection rate | Defined as the rate of pathogen detection for the current infection. | 30 days |
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Yeming Wang, M.D. | Contact | +86 84206264 | wwyymm_love@163.com | |
| Mengwei Yan | Contact | yanmengwei_happy@126.com |
| Name | Affiliation | Role |
|---|---|---|
| Binghuai Lu, M.D. | China-Japan Friendship Hospital | Principal Investigator |
| Bin Cao, M.D. | China-Japan Friendship Hospital | Study Chair |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| China-Japan Friendship hospital | Beijing | Beijing Municipality | 100029 | China |
IPD used in the results publication will be shared.
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D000098968 | Community-Acquired Pneumonia |
| ID | Term |
|---|---|
| D017714 | Community-Acquired Infections |
| D007239 | Infections |
| D011014 | Pneumonia |
| D012141 | Respiratory Tract Infections |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
|
| Conventional microbiological testing | Diagnostic Test | Bronchoalveolar lavage fluid (BALF) or sputum samples will be collected within 72 hours after randomization and sent for conventional microbiological testing. The type of conventional microbiological testing will be determined by the attending physician, and test results will be reported in approximately one week |
|
| Follow-up at Day 30 | Other | A telephone visit will be conducted on or around Day 30 for study participants who are discharged or transferred to another hospital due to disease exacerbation, to collect information on survival, ICU admissions, mechanical ventilation, and medical costs. |
|
| 30 days |
| Length of stay in ICU | Defined as the total number of days a patient spends in the ICU within 30 days of randomization | 30 days |
| Incidence of mechanical ventilation | Defined as the proportion of patients receiving mechanical ventilation by day 30. | 30 days |
| Duration of mechanical ventilation | Defined as the total number of days a patient receives mechanical ventilation within 30 days of randomization. | 30 days |
| 5-Day Antibiotic Modification Rate | Defined as the proportion of patients who undergo antibiotic escalation or de-escalation within 5 days after randomization. | 5 days |
| 3-Day Antibiotic Modification Rate | Defined as the proportion of patients who undergo antibiotic escalation or de-escalation within 3 days after randomization. | 3 days |
| 5-Day Other Antimicrobial Agents Modification Rate | Defined as the proportion of patients who initiate or discontinue other antimicrobial agents including antiviral, antifungal or antitubercular drugs within 5 days after randomization. | 5 days |
| 3-Day Other Antimicrobial Agents Modification Rate | Defined as the proportion of patients who initiate or discontinue other antimicrobial agents including antiviral, antifungal or antitubercular drugs within 3 days after randomization. | 3 days |
| Cost of hospitalization | Defined as the total expenses incurred for hospitalization related to the current infection within 30 days of randomization." | 30 days |
| D012140 |
| Respiratory Tract Diseases |